Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse
Abstract Background Graft-versus-host disease (GVHD) and relapse are major complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Metabolites play crucial roles in immune regulation, but their causal relationships with GVHD and relapse remain unclear. Methods We util...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-025-04026-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850183919386755072 |
|---|---|
| author | Xinghao Yu Yiyin Chen Lei Lei Pengfei Li Dandan Lin Ying Shen Chang Hou Jia Chen Yi Fan Yi Jin Huimin Lu Depei Wu Yang Xu |
| author_facet | Xinghao Yu Yiyin Chen Lei Lei Pengfei Li Dandan Lin Ying Shen Chang Hou Jia Chen Yi Fan Yi Jin Huimin Lu Depei Wu Yang Xu |
| author_sort | Xinghao Yu |
| collection | DOAJ |
| description | Abstract Background Graft-versus-host disease (GVHD) and relapse are major complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Metabolites play crucial roles in immune regulation, but their causal relationships with GVHD and relapse remain unclear. Methods We utilized genetic variants from genome-wide association studies (GWAS) of 309 known metabolites as instrumental variables to evaluate their causal effects on acute GVHD (aGVHD), gut GVHD, chronic GVHD (cGVHD), and relapse in different populations. Multiple causal inference methods, heterogeneity assessments, and pleiotropy tests were conducted to ensure result robustness. Multivariable MR analysis was performed to adjust for potential confounders, and validation MR analysis further confirmed key findings. Mediation MR analysis was employed to explore indirect causal pathways. Results After correction for multiple testing, we identified elevated pyridoxate and proline levels as protective factors against grade 3–4 aGVHD (aGVHD3) and relapse, respectively. Conversely, glycochenodeoxycholate increased the risk of aGVHD3, whereas 1-stearoylglycerophosphoethanolamine had a protective effect. The robustness and stability of these findings were confirmed by multiple causal inference approaches, heterogeneity, and horizontal pleiotropy analyses. Multivariable MR analysis further excluded potential confounding pleiotropic effects. Validation MR analyses supported the causal roles of pyridoxate and 1-stearoylglycerophosphoethanolamine, while mediation MR revealed that pyridoxate influences GVHD directly and indirectly via CD39 + Tregs. Pathway analyses highlighted critical biochemical alterations, including disruptions in bile acid metabolism and the regulatory roles of vitamin B6 derivatives. Finally, clinical metabolic analyses, including direct fecal metabolite measurements, confirmed the protective role of pyridoxate against aGVHD. Conclusions Our findings provide novel insights into the metabolic mechanisms underlying GVHD and relapse after allo-HSCT. Identified metabolites, particularly pyridoxate, may serve as potential therapeutic targets for GVHD prevention and management. |
| format | Article |
| id | doaj-art-7d889eab89ff47b7bfe716da494c1b3f |
| institution | OA Journals |
| issn | 1741-7015 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj-art-7d889eab89ff47b7bfe716da494c1b3f2025-08-20T02:17:10ZengBMCBMC Medicine1741-70152025-04-0123111910.1186/s12916-025-04026-wMendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapseXinghao Yu0Yiyin Chen1Lei Lei2Pengfei Li3Dandan Lin4Ying Shen5Chang Hou6Jia Chen7Yi Fan8Yi Jin9Huimin Lu10Depei Wu11Yang Xu12National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityDepartment of Pharmacy, Wujin Hospital Affiliated with Jiangsu UniversityDepartment of Outpatient and Emergency, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow UniversityAbstract Background Graft-versus-host disease (GVHD) and relapse are major complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Metabolites play crucial roles in immune regulation, but their causal relationships with GVHD and relapse remain unclear. Methods We utilized genetic variants from genome-wide association studies (GWAS) of 309 known metabolites as instrumental variables to evaluate their causal effects on acute GVHD (aGVHD), gut GVHD, chronic GVHD (cGVHD), and relapse in different populations. Multiple causal inference methods, heterogeneity assessments, and pleiotropy tests were conducted to ensure result robustness. Multivariable MR analysis was performed to adjust for potential confounders, and validation MR analysis further confirmed key findings. Mediation MR analysis was employed to explore indirect causal pathways. Results After correction for multiple testing, we identified elevated pyridoxate and proline levels as protective factors against grade 3–4 aGVHD (aGVHD3) and relapse, respectively. Conversely, glycochenodeoxycholate increased the risk of aGVHD3, whereas 1-stearoylglycerophosphoethanolamine had a protective effect. The robustness and stability of these findings were confirmed by multiple causal inference approaches, heterogeneity, and horizontal pleiotropy analyses. Multivariable MR analysis further excluded potential confounding pleiotropic effects. Validation MR analyses supported the causal roles of pyridoxate and 1-stearoylglycerophosphoethanolamine, while mediation MR revealed that pyridoxate influences GVHD directly and indirectly via CD39 + Tregs. Pathway analyses highlighted critical biochemical alterations, including disruptions in bile acid metabolism and the regulatory roles of vitamin B6 derivatives. Finally, clinical metabolic analyses, including direct fecal metabolite measurements, confirmed the protective role of pyridoxate against aGVHD. Conclusions Our findings provide novel insights into the metabolic mechanisms underlying GVHD and relapse after allo-HSCT. Identified metabolites, particularly pyridoxate, may serve as potential therapeutic targets for GVHD prevention and management.https://doi.org/10.1186/s12916-025-04026-wAllogeneic hematopoietic cell transplantationGraft-versus-host diseaseMetaboliteImmune cellMediationMendelian randomization |
| spellingShingle | Xinghao Yu Yiyin Chen Lei Lei Pengfei Li Dandan Lin Ying Shen Chang Hou Jia Chen Yi Fan Yi Jin Huimin Lu Depei Wu Yang Xu Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse BMC Medicine Allogeneic hematopoietic cell transplantation Graft-versus-host disease Metabolite Immune cell Mediation Mendelian randomization |
| title | Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse |
| title_full | Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse |
| title_fullStr | Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse |
| title_full_unstemmed | Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse |
| title_short | Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse |
| title_sort | mendelian randomization analysis of blood metabolites and immune cell mediators in relation to gvhd and relapse |
| topic | Allogeneic hematopoietic cell transplantation Graft-versus-host disease Metabolite Immune cell Mediation Mendelian randomization |
| url | https://doi.org/10.1186/s12916-025-04026-w |
| work_keys_str_mv | AT xinghaoyu mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT yiyinchen mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT leilei mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT pengfeili mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT dandanlin mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT yingshen mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT changhou mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT jiachen mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT yifan mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT yijin mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT huiminlu mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT depeiwu mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse AT yangxu mendelianrandomizationanalysisofbloodmetabolitesandimmunecellmediatorsinrelationtogvhdandrelapse |